Innovative Genetic Approach to Treating Depression and Anxiety

Many people struggle to find the right treatment for depression or anxiety, as prescribed medications often fail to work on the first try. It may take trying multiple drugs over weeks or even months before achieving the desired relief. However, there is new hope on the horizon thanks to an innovative genetic approach.

The Genetic Approach in New Research

A research team from Germany, Sweden, and Denmark is working on developing a genetic approach that could help doctors predict which antidepressants or anti-anxiety medications will be most effective for a particular individual. This method relies on what is known as polygenic risk scores, which analyze a person’s DNA to assess how genetic variations may influence their response to certain medications.

These genetic tests allow doctors to estimate which medications might be most effective for a patient. Although this technique has only been tested using genetic research databases, the results so far are promising.

Applications of Genetic Methods in Psychiatry

The team leader, Professor Fredrik Aas from Mid Sweden University, hopes to move the research into clinical trials soon. Aas states, “We believe this technology can be used to develop more targeted tests, with the long-term goal of a test that doctors can use to choose the right medication.”

The project began two years ago when Aas contacted Professor Doug Speed from Aarhus University in Denmark, who has spent years refining methods for analyzing complex genetic data, particularly related to psychiatric disorders.

Understanding Polygenic Risk Scores

Since the beginning of the 21st century, scientists have discovered thousands of small variations in DNA that can affect health. Humans have about 20,000 genes, and each gene has multiple versions, some of which are associated with an increased likelihood of developing specific diseases.

Researchers compile this information to create polygenic risk scores, which are tools that aggregate the effects of many genetic variations to estimate the risk of developing certain conditions.

Challenges and Opportunities in Using Genetic Data

Aas and his team applied polygenic risk scores to data from the Swedish Twin Registry, allowing them to compare the effects of genes and the environment on health and behavior. The researchers found that medications like benzodiazepines and histamines had less effect on individuals with high genetic risk scores for depression or anxiety.

While the study showed promising results, it has some limitations, such as a lack of complete data on why patients changed their medications. Therefore, the team looks forward to conducting follow-up clinical studies to improve the accuracy of the results.

Conclusion

Despite the need for more research, the results indicate a future where choosing antidepressants may not rely on trial and error. A simple genetic test could help doctors match patients with the most effective treatment from the start, saving time, reducing side effects, and improving the lives of millions around the world.